Novartis Pharmaceuticals Australia Pty Ltd / Novartis Pharmaceuticals Pty Ltd / The Haematological Society of Australia / /
Facility
The Sheraton Hotel / /
IndustryTerm
prognosis scoring systems / /
MedicalCondition
fatigue / PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS / severe disease / patient groups myelofibrosis / itchiness / myelofibrosis / /
Organization
PBAC’s Drug Utilisation Sub Committee / Pharmaceutical Benefits Advisory Committee / Haematological Society of Australia and New Zealand / Department of Health / Drug Utilisation Sub Committee / Leukaemia Foundation / Therapeutic Goods Administration / /
PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS 22 September 2014 The Sheraton Hotel, Melbourne Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), the consumer representa